Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the <scp>United States</scp>
Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the <scp>United States</scp> is a paper indexed in PICO Portal from OpenAlex.
How many citations does Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the <scp>United States</scp> have?
Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the <scp>United States</scp> has 40 citations in the OpenAlex counts PICO Portal stores.
When was Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the <scp>United States</scp> published?
Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the <scp>United States</scp> has 2021 year in the PICO Portal index.
What is the open-access status of Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the <scp>United States</scp>?
Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the <scp>United States</scp> has closed oa status in the PICO Portal index.
What is the DOI of Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the <scp>United States</scp>?
The DOI for Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the <scp>United States</scp> is on the source record.
What is the PMID of Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the <scp>United States</scp>?
The PMID for Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the <scp>United States</scp> is on the source record.
What is the OpenAlex record for Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the <scp>United States</scp>?
The OpenAlex for Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the <scp>United States</scp> is on the source record.